
Our vision is to be a leader in cancer immunotherapy improving patient treatment through novel monoclonal antibodies, inducing programmed cell death in cancer cells. Cancer treatment has generally been based on treatment with drugs and modalities that are cytotoxic to both cancer and healthy cells. Advances in immunotherapy open new possibilities for selective targeting of cancer cells. Caedo Oncology develops new strategies for monoclonal antibody-based therapy centered around activation of distinctive pathways for cell death in cancer cells. The company was established in November 2020…
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.